-
Mashup Score: 5Care for Patients with Nonmetastatic Castration-Resistant Prostate Cancer - Hanan Goldberg - 11 month(s) ago
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this patient category. They ponder the treatment conundrum posed by early detection of metastasis, not covered under current FDA approvals for medications like enzalutamide, apalutamide, and darolutamide, which…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 5Care for Patients with Nonmetastatic Castration-Resistant Prostate Cancer - Hanan Goldberg - 11 month(s) ago
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this patient category. They ponder the treatment conundrum posed by early detection of metastasis, not covered under current FDA approvals for medications like enzalutamide, apalutamide, and darolutamide, which…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Care for patients with nonmetastatic castration-resistant #ProstateCancer. @GoldbergHanan @UrologyUpstate and @zklaassen_md @GACancerCenter discuss this evolving landscape and the impact of PSMA PET scans on diminishing this patient category. #WatchNow > https://t.co/D3BG2ENeLl https://t.co/u1BlrNxp3B
-
-
Mashup Score: 9Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer - 11 month(s) ago
Alicia Morgans hosts a discussion with Paul Eber and Brad Somer to explore the collaborative management of metastatic hormone-sensitive prostate cancer cases. They highlight a unique partnership between urology and medical oncology in Memphis, Tennessee, emphasizing the importance of teamwork in treating patients, especially in underserved areas. Dr. Eber shares his experience with patients…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Teamwork and Trust: Keys to seamless #ProstateCancer care across specialties. Paul Eber & @bsomer @west_cancer join @CaPsurvivorship @DanaFarber to discuss their collaborative management of metastatic hormone-sensitive prostate cancer cases. #WatchNow > https://t.co/rJ0LxsWVRV https://t.co/wMP1gqZ7wb
-
-
Mashup Score: 22Optimizing Treatment in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study Analysis - Alicia Morgans - 11 month(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Elena Castro, MD, PhD, Hospital…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Optimizing treatment in metastatic hormone-sensitive #ProstateCancer: a case study analysis. @CaPsurvivorship @DanaFarber joins @Ecastromarcos in discussing the State of the Art of prostate cancer in 2024. #WatchNow on UroToday > https://t.co/KJqkw78cMy @BayerPharma https://t.co/xDq72orRs4
-
-
Mashup Score: 6Incorporating PSMA PET Into Radiotherapy Planning: Impact on Definitive Therapy "Presentation" - Nicholas Nickols - 12 month(s) ago
At the 2024 UCSF-UCLA PSMA Conference, Nicholas Nickols elucidates the evolution of prostate cancer imaging, crediting PSMA PET with transitioning it into a highly imaged disease, and discusses its integration into radiotherapy planning for enhanced precision and personalization in treatment. Dr. Nickols highlights the role of PSMA PET in refining radiation oncology through improved target…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Incorporating PSMA PET into radiotherapy planning: Impact on definitive therapy. Nicholas Nickols dives into the evolution of #ProstateCancer imaging. #WatchNow on UroToday > https://t.co/YNUsIc7kVA @PSMAconference @UCSF @UCLA @PCFnews https://t.co/6eNjdHHg5f
-
-
Mashup Score: 15PSMA PET Appropriate Use Criteria "Presentation" - Michael Morris - 12 month(s) ago
At the 2024 UCSF-UCLA PSMA Conference, Michael Morris highlights the importance of PSMA PET in prostate cancer management, acknowledging the regulatory framework established by pivotal trials that led to FDA approval for PSMA PET tracers. Dr. Morris discusses the challenges of interpreting PSMA PET results, the need for consensus in its application, particularly in biochemical recurrence and…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Exciting insights from the 2024 @UCSF @UCLA @PSMAconference! @morr316 @MSKCancerCenter emphasized the pivotal role of PSMA PET in #ProstateCancer mgmt, navigating its regulatory journey and challenges in interpretation. #WatchNow > https://t.co/MogaNNDpBO @PCFnews https://t.co/zaamkLvLQv
-
-
Mashup Score: 5The Use of Imaging in Staging Localized Prostate Cancer: A Case Study on High-Risk Localized Prostate Cancer - Zachary Klaassen - 12 month(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Well Star MCG, Georgia Cancer Center, Augusta, GA Neal D….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Join Neal Shore @CURCMB, and @zklaassen_md @GACancerCenter as they delve into the groundbreaking use of PSMA PET imaging in high-risk localized #ProstateCancer. Learn how this innovative technology is transforming patient care. #WatchNow > https://t.co/iCBdBAzf5i @BayerPharma https://t.co/naUJmf3PSG
-
-
Mashup Score: 5Care for Patients with Nonmetastatic Castration-Resistant Prostate Cancer - Hanan Goldberg - 12 month(s) ago
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this patient category. They ponder the treatment conundrum posed by early detection of metastasis, not covered under current FDA approvals for medications like enzalutamide, apalutamide, and darolutamide, which…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Care for patients with nonmetastatic castration-resistant #ProstateCancer. @GoldbergHanan @UrologyUpstate and @zklaassen_md @GACancerCenter discuss this evolving landscape and the impact of PSMA PET scans on diminishing this patient category. #WatchNow > https://t.co/D3BG2ENeLl https://t.co/u1BlrNxp3B
-
-
Mashup Score: 0PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer - Louise Emmett - 12 month(s) ago
In a conversation with Phillip Koo, Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. They explore the significance of key trials such as ENZA-p, VISION, TheraP, PSMAfore, SPLASH, and ECLIPSE, examining the challenges in proving overall survival benefits and the potential of adaptive dosing strategies for improved patient outcomes. Emmett…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
PSMA-targeted radionuclide therapy in the pre- and post-chemotherapy settings in #ProstateCancer. @drlouiseemmett and @PhillipKooMD discuss the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. #WatchNow > https://t.co/X3lgHdV6P5 https://t.co/qDLqTFIXOr
-
-
Mashup Score: 16Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer - Alexander Wyatt - 1 year(s) ago
Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients’ prostates and lymph nodes, the study uncovers significant genomic…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Comprehensive multi-region sampling reveals extensive genomic heterogeneity in metastatic #ProstateCancer. @ResearchWyatt @VanProstateCtr joins @AndreaMiyahira @PCFnews in this conversation on a study of de novo metastatic prostate cancer. #WatchNow > https://t.co/WtoQpoTzv0 https://t.co/XeKTJadGfo
-
Care for patients with nonmetastatic castration-resistant #ProstateCancer. @GoldbergHanan @UrologyUpstate and @zklaassen_md @GACancerCenter discuss this evolving landscape and the impact of PSMA PET scans on diminishing this patient category. #WatchNow > https://t.co/D3BG2ENeLl https://t.co/u1BlrNxp3B